Fmr LLC Cytom X Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 242,358 shares of CTMX stock, worth $288,406. This represents 0.0% of its overall portfolio holdings.

Number of Shares

242,358

Previous 183,077 32.38%

Holding current value

$288,406

Previous $399,000 26.07%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.21 - $5.13 $71,730 - $304,111	59,281 Added 32.38%	242,358 $295,000
Q1 2024 May 13, 2024	SELL	$1.41 - $2.74 $538,968 - $1.05 Million	-382,247 Reduced 67.62%	183,077 $399,000
Q4 2023 Feb 13, 2024	SELL	$1.07 - $1.55 $152,629 - $221,098	-142,644 Reduced 20.15%	565,324 $876,000
Q3 2023 Nov 13, 2023	SELL	$1.26 - $1.87 $24,459 - $36,300	-19,412 Reduced 2.67%	707,968 $913,000
Q2 2023 Aug 11, 2023	BUY	$1.41 - $1.92 $30,573 - $41,631	21,683 Added 3.07%	727,380 $1.25 Million
Q1 2023 May 11, 2023	SELL	$1.48 - $2.88 $16,204 - $31,533	-10,949 Reduced 1.53%	705,697 $1.07 Million
Q4 2022 Feb 13, 2023	BUY	$1.19 - $1.91 $17,938 - $28,791	15,074 Added 2.15%	716,646 $1.15 Million
Q3 2022 Nov 10, 2022	SELL	$1.23 - $1.97 $2,013 - $3,224	-1,637 Reduced 0.23%	701,572 $1.02 Million
Q2 2022 Aug 12, 2022	BUY	$1.53 - $2.89 $2,129 - $4,022	1,392 Added 0.2%	703,209 $1.29 Million
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $441,569 - $773,987	165,382 Added 30.83%	701,817 $1.87 Million
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $1.97 Million - $3.76 Million	-509,185 Reduced 48.7%	536,435 $2.32 Million
Q2 2021 Aug 13, 2021	BUY	$6.33 - $9.91 $6.62 Million - $10.4 Million	1,045,620 New	1,045,620 $6.62 Million

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.2M

Call Options Held

22.3K

Put Options Held

22.9K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $78.5M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account